CRP, as a marker of systemic inflammation in HCV patients, was evaluated and showed a highly significant improvement in all patient subgroups at the end of treatment.
← all excerpts
Cardiac safety of sofosbuvir-based direct-acting antivirals in hepatitis C patients with pre-existing heart disease.
1
—
—